Thymidylate synthase inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “Thymidylate synthase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Thymidylate synthase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Thymidylate synthase inhibitors: Overview
Thymidylate synthetase is an important enzyme, which is responsible for the reductive methylation of deoxyuridylic acid (dUMP) to deoxythymidylic acid (dTMP). The methylation of the uracil moiety (present in RNA) to 5-methyl uracil (thymine, present in DNA) requires participation of a folic acid coenzyme, N5, N10-methylenetetrahydrofolate as a methyl donor. Thymidylate synthase inhibitors are chemical agents which inhibit the enzyme thymidylate synthase and have potential as an anticancer chemotherapy.[1] This inhibition prevents the methylation of C5 of deoxyuridine monophosphate (dUMP) thereby inhibiting the synthesis of deoxythymidine monophosphate (dTMP).
Report Highlights
This segment of the Thymidylate synthase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Thymidylate synthase inhibitors Emerging Drugs
Further product details are provided in the report……..
Thymidylate synthase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Thymidylate synthase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Thymidylate synthase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Thymidylate synthase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Thymidylate synthase inhibitors drugs.
Thymidylate synthase inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Thymidylate synthase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Thymidylate synthase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Thymidylate synthase inhibitors: Overview
Thymidylate synthetase is an important enzyme, which is responsible for the reductive methylation of deoxyuridylic acid (dUMP) to deoxythymidylic acid (dTMP). The methylation of the uracil moiety (present in RNA) to 5-methyl uracil (thymine, present in DNA) requires participation of a folic acid coenzyme, N5, N10-methylenetetrahydrofolate as a methyl donor. Thymidylate synthase inhibitors are chemical agents which inhibit the enzyme thymidylate synthase and have potential as an anticancer chemotherapy.[1] This inhibition prevents the methylation of C5 of deoxyuridine monophosphate (dUMP) thereby inhibiting the synthesis of deoxythymidine monophosphate (dTMP).
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Thymidylate synthase inhibitors R&D. The therapies under development are focused on novel approaches for Thymidylate synthase inhibitors.
This segment of the Thymidylate synthase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Thymidylate synthase inhibitors Emerging Drugs
- ADX 2191: Aldeyra Therapeutics
- LY-01616: Luye Pharma
Further product details are provided in the report……..
Thymidylate synthase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Thymidylate synthase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Thymidylate synthase inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Thymidylate synthase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Thymidylate synthase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Thymidylate synthase inhibitors drugs.
Thymidylate synthase inhibitors Report Insights
- Thymidylate synthase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Thymidylate synthase inhibitors drugs?
- How many Thymidylate synthase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Thymidylate synthase inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Thymidylate synthase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Thymidylate synthase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Aldeyra Therapeutics
- Luye Pharma Group
- Nucana BioMed
- Roche
- ROS Therapeutics
- Nordic Group
- Taiho Pharmaceutical
- Fivephusion
- Isofol Medical
- Eli Lilly and Company
- Nucana BioMed
- Mebiopharm
- Atlanthera
- SetLance
- Cardiol Therapeutics
- Venus Remedies
- Lumosa Therapeutics
- Celator Pharmaceuticals
- Sanofi
- ADX 2191
- LY01616
- Fosifloxuridine nafalbenamide
- Capecitabine
- SAR-439281
- NUC 3373
- MBP Y003
- CTX02
- VRT 002 P
- CPX-1
- LT 2003
- Research programme - neurotensin conjugated anticancer therapies
- 1102-39
- Methotrexate prodrug
- Nordimet
- Pemetrexed
- SP-05
- TS-1
- LV/5-FU
Introduction
Executive Summary
Thymidylate synthase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Thymidylate synthase inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
ADX 2191: Aldeyra Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
SAR-439281: Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Fosifloxuridine nafalbenamide: Nucana BioMed
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Methotrexate prodrug: ROS Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Thymidylate synthase inhibitors Key Companies
Thymidylate synthase inhibitors Key Products
Thymidylate synthase inhibitors- Unmet Needs
Thymidylate synthase inhibitors- Market Drivers and Barriers
Thymidylate synthase inhibitors- Future Perspectives and Conclusion
Thymidylate synthase inhibitors Analyst Views
Thymidylate synthase inhibitors Key Companies
Appendix
Executive Summary
Thymidylate synthase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Thymidylate synthase inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
ADX 2191: Aldeyra Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
SAR-439281: Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Fosifloxuridine nafalbenamide: Nucana BioMed
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Methotrexate prodrug: ROS Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Thymidylate synthase inhibitors Key Companies
Thymidylate synthase inhibitors Key Products
Thymidylate synthase inhibitors- Unmet Needs
Thymidylate synthase inhibitors- Market Drivers and Barriers
Thymidylate synthase inhibitors- Future Perspectives and Conclusion
Thymidylate synthase inhibitors Analyst Views
Thymidylate synthase inhibitors Key Companies
Appendix